Reviewed October 30, 2026 · Research-use information
the short answer
No one knows. There is no validated canine time-to-effect or PK study for TB-500, and no controlled canine trials at all. TB-500 is a research peptide, not an FDA-approved veterinary drug. A 2026 orthopaedic review says validated dosing, pharmacokinetic, and long-term safety data are lacking. A timeline would need controlled canine studies. Until then, track function with your vet rather than watching a calendar.
| Question | What exists | What it means |
|---|---|---|
| Canine onset study | None identified | No time-to-effect endpoint in dogs |
| Canine pharmacokinetics | No validated dataset for the pen | The 2026 review says PK data are lacking |
| Human TB-500 exposure data | None identified by FDA | No human safety or efficacy dataset for the fragment |
| TB-4 study data | Not TB-500 data | TB-500 is a distinct fragment; equivalence is not validated |
| 28-day pen window | A review point | Not a promised onset |
A status table, not a schedule. Reviewed October 30, 2026.
Why there is no honest TB-500 timeline
A timeline needs a defined endpoint, a controlled comparison, and enough dogs to separate the peptide from rest, time, and other care. TB-500 has none of that in dogs. No controlled canine trials have been completed, there is no validated canine PK dataset for the pen, and the 2026 orthopaedic review says validated dosing, pharmacokinetic, and long-term safety data are lacking. A forum timeline is not evidence. Extrapolating from a rodent study or a full-length thymosin beta-4 study is not a canine onset finding.
TB-500 is not TB-4
TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4, sometimes written as LKKTETQ. The 2026 review says the two are frequently conflated despite no validated biologic or clinical equivalence. Thymosin beta-4 has broader experimental and human experience in ophthalmic, dermatologic, and cardiovascular applications, but its direct musculoskeletal evidence remains limited to in-vitro and rodent studies. Those findings cannot establish a TB-500 onset timeline in dogs, and they do not make the two molecules interchangeable.
What the FDA says
The FDA's bulk-substance page says compounded drugs containing the thymosin beta-4 fragment known as TB-500 may pose a risk for immunogenicity due to the potential for aggregation, as well as peptide-related impurities. The agency says it has not identified any human exposure data for the fragment and lacks important safety information, including whether it would cause harm. That is regulatory caution, not an onset timeline. It is also not a canine safety study.
What a real onset study would need
A useful study would use a standardized product, a defined dose and route, a validated assay, a blinded functional endpoint, enough dogs to see a real difference, and follow-up long enough to catch delayed effects. It would need to separate the peptide from usual care and report adverse events. Until that exists, no one can honestly say day 7, day 14, or day 30. For this pen, the 28-day window is a review point, not a promised onset.
What to track instead of a date
Track function: how long it takes your dog to rise, whether they hesitate at stairs, how far they walk before stopping, and whether they will jump. Add appetite, sleep, and pain signs. A weekly video of the same walk is more useful than a memory. Bring the log to your vet. Do not wait for the 28-day review if your dog is suddenly lame, yelping, dragging a leg, unable to bear weight, or having trouble urinating.
What we do not claim
- We do not claim a 7-day, 14-day, or 30-day TB-500 onset.
- We do not claim TB-4 or rodent data predict a canine timeline.
- We do not claim the 28-day pen window is proof of effect.
- We do not claim TB-500 is a cure or an FDA-approved drug.
Sources
Reviewed October 30, 2026. These are the sources we used for this page. Dollar figures, where present, are estimates from the named source, not quotes.
- PubMed: Investigational peptides in orthopaedic practice (2026)Tham et al., JAAOS. TB-500 is a distinct TB-4 fragment; direct musculoskeletal evidence is limited to in-vitro and rodent studies; validated dosing and PK data are lacking.
- FDA: Certain Bulk Drug Substances for Use in CompoundingTB-500 aggregation, immunogenicity, and impurity concerns; no human exposure data for the fragment; content current April 22, 2026.
- AVMA: Your pet's medicationsHuman doses can differ widely from dog doses; ask your vet about any medication or supplement.
Questions owners ask
How long does TB-500 take to work in dogs?
No one knows. No validated canine time-to-effect or PK study exists, and no controlled canine trials have been completed. The 2026 orthopaedic review says validated dosing, pharmacokinetic, and long-term safety data are lacking.
Can I use thymosin beta-4 study timelines?
No. TB-500 is a seven-amino-acid fragment of TB-4, and the 2026 review says the two are often conflated without validated biologic or clinical equivalence. TB-4 data are not a TB-500 schedule.
Is there a loading phase for TB-500 in dogs?
No validated TB-500 loading protocol exists for dogs. Do not borrow one from a human forum or a vial label. Ask your vet what, if anything, they would monitor.
When should I call the vet?
Call for sudden lameness, yelping, dragging a leg, inability to bear weight, trouble urinating, or a reaction at the injection site. Facial swelling, trouble breathing, or collapse is an emergency.